Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?

NCT ID NCT07725874

Disease control Sponsor: Beijing Friendship Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

Invasive mold infections are a major threat to liver transplant recipients, with mortality rates as high as 90%. The standard treatment, voriconazole, can interfere with anti-rejection drugs, increasing the risk of graft loss. This trial tests whether liposomal amphotericin B (AmBisome) can safely and effectively treat these infections without those dangerous drug interactions. The study will follow 60 liver transplant patients receiving AmBisome in real-world conditions, closely monitoring for side effects like kidney damage and electrolyte imbalances.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomal amphotericin B (AmBisome)
What this could lead to
If this trial succeeds, it could provide strong evidence for using liposomal amphotericin B as a first-line treatment for invasive mold infections in liver transplant recipients, potentially reducing the risk of graft rejection compared to current alternatives.
What could go wrong
This is a small, single-center, real-world study with no fixed dosing, which limits the strength of conclusions. Liposomal amphotericin B can cause kidney damage, electrolyte imbalances, and infusion reactions, especially in already vulnerable transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients aged ≥12 years. Liver transplant recipients. Proven or probable invasive mold disease (IMD) according to the 2020 EORTC/MSGERC criteria. Have received at least one dose of liposomal amphotericin B (AmBisome) or voriconazole. Exclusion Criteria: History of invasive mold disease previously treated with amphotericin B for more than 5 days. Documented hypersensitivity or allergy to amphotericin B formulations. Sequential Organ Failure Assessment (SOFA) score \>15. Expected survival \<72 hours. Pregnant or breastfeeding. Patients who, in the investigator's judgment, are unable to complete the study treatment or follow the study protocol. Recipients of combined organ transplantation or multivisceral transplantation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive aspergillosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive aspergillosis Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive mold diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.